Patents by Inventor Todd A. Blumenkopf

Todd A. Blumenkopf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrrolo[2,3-D]pyrimidine compounds
    Publication number: 20040053947
    Abstract: A compound of the formula 1
    Type: Application
    Filed: August 13, 2003
    Publication date: March 18, 2004
    Applicant: Pfizer Inc.
    Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Michael J. Munchhof
  • Pyrrolo[2,3-d]pyrimidine compounds
    Patent number: 6696567
    Abstract: A compound of the formula wherein R1, R2 and R3 are as defined above, useful as inhibitors of protein kinases, such as the enzyme Janus Kinase 3.
    Type: Grant
    Filed: June 25, 2001
    Date of Patent: February 24, 2004
    Assignee: Pfizer Inc.
    Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Michael J. Munchhof
  • Pyrrolo[2,3-d]pyrimidine compounds
    Publication number: 20030220353
    Abstract: A compound of the formula 1
    Type: Application
    Filed: June 16, 2003
    Publication date: November 27, 2003
    Applicant: Pfizer Inc.
    Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Michael J. Munchhof
  • Pyrrolo [2,3-D] pyrimidine compounds
    Publication number: 20030212273
    Abstract: A compound of the formula 1
    Type: Application
    Filed: May 20, 2003
    Publication date: November 13, 2003
    Applicant: Pfizer Inc.
    Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Matthew F. Brown, Paul S. Changelian
  • Monocyclic-7H-pyrrolo[2,3-d]pyrimidine compounds, compositions, and methods of use
    Patent number: 6635762
    Abstract: Novel pyrrolo[2,3-d]pyrimidine compounds useful as inhibitors of the enzyme protein tyrosine kinases such as Janus Kinase 3 as well as immunosuppressive agents for organ transplants, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases are described.
    Type: Grant
    Filed: June 17, 1999
    Date of Patent: October 21, 2003
    Assignee: Pfizer Inc.
    Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Matthew F. Brown, Paul S. Changelian
  • 2,4-Diaminopyrimidine compounds useful as immunosuppressants
    Publication number: 20030191307
    Abstract: Novel compounds according to the formula 1
    Type: Application
    Filed: November 22, 2002
    Publication date: October 9, 2003
    Inventors: Todd A. Blumenkopf, Eileen Elliott Mueller, Eric Jan Roskamp
  • Pyrrolo[2,3-d]pyrimidine compounds
    Patent number: 6627754
    Abstract: A compound of the formula wherein R1, R2 and R3 are as defined above, which are inhibitors of the enzyme protein kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, xeno transplation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.
    Type: Grant
    Filed: December 8, 2000
    Date of Patent: September 30, 2003
    Assignee: Pfizer Inc.
    Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Michael J. Munchhof
  • Pyrrolo[2,3-d]pyrimidine compounds
    Patent number: 6610847
    Abstract: A compound of the formula wherein R1, R2 and R3 are as defined above, which are inhibitors of the enzyme protein tyrosine kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.
    Type: Grant
    Filed: September 19, 2001
    Date of Patent: August 26, 2003
    Assignee: Pfizer Inc.
    Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Matthew F. Brown, Paul S. Changelian
  • Pyrrolo[2,3-d]pyrimidine compounds
    Publication number: 20020068746
    Abstract: A compound of the formula 1
    Type: Application
    Filed: June 25, 2001
    Publication date: June 6, 2002
    Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Michael J. Munchhof
  • Pyrrolo[2,3-d]pyrimidine compounds
    Publication number: 20020019526
    Abstract: A compound of the formula 1
    Type: Application
    Filed: September 19, 2001
    Publication date: February 14, 2002
    Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Matthew F. Brown, Paul S. Changelian
  • Pyrrolo[2,3-d]pyrimidine compounds
    Publication number: 20010053782
    Abstract: A compound of the formula 1
    Type: Application
    Filed: December 8, 2000
    Publication date: December 20, 2001
    Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Michael J. Munchhof
  • Arylsulfonylamino hydroxamic acid derivatives
    Patent number: 6153609
    Abstract: A compound of the formula ##STR1## wherein n, X, R.sup.3, R.sup.4 and Q are as defined above, useful in the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, macular degeneration, restenosis, periodontal disease, epidermolysis bullosa, scleritis, and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of TNF. In addition, the compounds of the present invention may be used in combination therapy with standard non-steroidal anti-inflammatory drugs (NSAID'S) and analgesics, and in combination with cytotoxic drugs such as adriamycin, daunomycin, cis-platinum, etoposide, taxol, taxotere and other alkaloids, such as vincristine, in the treatment of cancer.
    Type: Grant
    Filed: February 16, 1999
    Date of Patent: November 28, 2000
    Assignee: Pfizer Inc
    Inventors: Ralph P. Robinson, Todd A. Blumenkopf
  • Antiviral compositions consisting of acyclovir and a 2-acetyl pyridine derivative
    Patent number: 5405850
    Abstract: The present invention relates to a novel ribonucleotide reductase inhibitor and new combinations comprising an antiviral compound, such as acyclovir, and a thiocarbonohydrazone ribonucleotide reductase inhibitor for the chemo-therapeutic treatment of virus infections, especially viruses of the herpes group.
    Type: Grant
    Filed: October 29, 1992
    Date of Patent: April 11, 1995
    Assignee: Burroughs Wellcome Co.
    Inventor: Todd A. Blumenkopf
  • Antiviral combinations and compounds therefor
    Patent number: 5175165
    Abstract: The present invention relates to novel ribonucleotide reductase inhibitors and new combinations comprising an antiviral compound, such as acyclovir, and a thiocarbonohydrazone ribonucleotide reductase inhibitor for the chemotherapeutic treatment of virus infections, espectially viruses of the herpes group.
    Type: Grant
    Filed: June 26, 1989
    Date of Patent: December 29, 1992
    Assignee: Burroughs Wellcome Co.
    Inventors: Todd A. Blumenkopf, Thomas Spector, Devron R. Averett, Robert W. Morrison, Jr., Eric C. Bigham, Virgil L. Styles
  • Antiviral acetyl pyridine derivative or said acetyl pyridine derivative in combination with acyclovir
    Patent number: 5164395
    Abstract: The present invention relates to a novel ribonucleotide reductase inhibitor and new combinations comprising an antiviral compound, such as acyclovir, and a thiocarbonohydrazone ribonucleotide reductase inhibitor for the chemotherapeutic treatment of virus infections, especiallly viruses of the herpes group.
    Type: Grant
    Filed: March 1, 1991
    Date of Patent: November 17, 1992
    Assignee: Burroughs Wellcome Co.
    Inventor: Todd A. Blumenkopf
  • 2-acetylpyridine 5-[(2-chloroanilino)thiocarbonyl]thiocarbonohydrazone compound and salts thereof
    Patent number: 5021437
    Abstract: The present invention relates to a novel ribonucleotide reductase inhibitor and new combinations comprising an antiviral compound, such as acyclovir, and a thiocarbonohydrazone ribonucleotide reductase inhibitor for the chemotherapeutic treatment of virus infections, especially viruses of the herpes group.
    Type: Grant
    Filed: June 26, 1989
    Date of Patent: June 4, 1991
    Assignee: Burroughs Wellcome Co.
    Inventor: Todd A. Blumenkopf